CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by C M Bidwell & Associates Ltd.

C M Bidwell & Associates Ltd. lessened its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 74.3% in the 4th quarter, Holdings Channel reports. The firm owned 802 shares of the company’s stock after selling 2,317 shares during the period. C M Bidwell & Associates Ltd.’s holdings in CRISPR Therapeutics were worth $50,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. ARK Investment Management LLC raised its holdings in shares of CRISPR Therapeutics by 19.2% during the fourth quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock valued at $534,360,000 after acquiring an additional 1,372,986 shares during the last quarter. Capital International Investors lifted its holdings in CRISPR Therapeutics by 0.8% in the 4th quarter. Capital International Investors now owns 6,134,450 shares of the company’s stock valued at $384,017,000 after purchasing an additional 48,938 shares in the last quarter. Vanguard Group Inc. boosted its stake in CRISPR Therapeutics by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,538,725 shares of the company’s stock worth $69,843,000 after purchasing an additional 7,635 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of CRISPR Therapeutics by 2.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 653,023 shares of the company’s stock worth $40,879,000 after buying an additional 15,085 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at about $38,661,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Oppenheimer dropped their price objective on shares of CRISPR Therapeutics from $102.00 to $95.00 and set an “outperform” rating for the company in a research note on Friday, May 10th. Morgan Stanley lifted their price objective on CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an “underweight” rating in a research report on Monday, February 26th. Needham & Company LLC dropped their target price on CRISPR Therapeutics from $90.00 to $88.00 and set a “buy” rating for the company in a report on Thursday, May 9th. Wells Fargo & Company reduced their price target on CRISPR Therapeutics from $70.00 to $65.00 and set an “equal weight” rating on the stock in a report on Thursday, May 9th. Finally, Royal Bank of Canada upped their price objective on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a report on Thursday, February 22nd. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $73.46.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of the stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $72.48, for a total value of $1,449,600.00. Following the sale, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at approximately $15,084,682.56. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CFO Raju Prasad sold 3,524 shares of CRISPR Therapeutics stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $72.69, for a total transaction of $256,159.56. Following the sale, the chief financial officer now owns 6,476 shares in the company, valued at $470,740.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Samarth Kulkarni sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $72.48, for a total value of $1,449,600.00. Following the completion of the sale, the chief executive officer now owns 208,122 shares of the company’s stock, valued at approximately $15,084,682.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 43,106 shares of company stock valued at $2,878,917. 4.10% of the stock is currently owned by corporate insiders.

CRISPR Therapeutics Stock Up 4.0 %

Shares of CRSP opened at $64.83 on Thursday. CRISPR Therapeutics AG has a fifty-two week low of $37.55 and a fifty-two week high of $91.10. The company has a market cap of $5.51 billion, a P/E ratio of -23.83 and a beta of 1.78. The firm’s 50 day moving average price is $57.09 and its 200 day moving average price is $65.25.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The firm had revenue of $0.50 million during the quarter, compared to analyst estimates of $25.53 million. During the same quarter in the prior year, the firm posted ($0.67) EPS. The company’s quarterly revenue was down 99.5% on a year-over-year basis. Research analysts forecast that CRISPR Therapeutics AG will post -5.51 earnings per share for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.